Solifenacin/tamsulosin - Jeil Pharmaceutical

Drug Profile

Solifenacin/tamsulosin - Jeil Pharmaceutical

Alternative Names: JLP-1207

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jeil Pharmaceutical
  • Class Antispasmodics; Quinuclidines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia
  • Phase I Overactive bladder

Most Recent Events

  • 25 May 2015 Jeil Pharmaceutical plans a phase I drug interaction study in healthy volunteers in South Korea (NCT02447367)
  • 01 Mar 2015 Jeil Pharmaceutical completes a pharmacokinetic drug interaction phase I trial (In volunteers) in South Korea (NCT02180997)
  • 01 Jul 2014 Preclinical trials in Benign prostatic hyperplasia and Overactive bladder in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top